Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:medical_condition
|
| gptkbp:affects |
gptkb:nervous_system
cardiovascular system muscular system metabolic system |
| gptkbp:alsoKnownAs |
sympathomimetic syndrome
|
| gptkbp:associatedWith |
overdose
drug abuse illicit drug use |
| gptkbp:cause |
gptkb:arrhythmias
acute renal failure myocardial infarction stroke seizures metabolic acidosis hyperglycemia rhabdomyolysis |
| gptkbp:causedBy |
gptkb:ephedrine
gptkb:theophylline gptkb:MDMA gptkb:amphetamine gptkb:pseudoephedrine cocaine caffeine amphetamines |
| gptkbp:characterizedBy |
hypertension
mydriasis tachycardia hyperthermia agitation diaphoresis |
| gptkbp:diagnosedBy |
clinical presentation
|
| gptkbp:differentialDiagnosis |
gptkb:serotonin_syndrome
gptkb:anticholinergic_toxicity malignant hyperthermia neuroleptic malignant syndrome |
| gptkbp:firstDescribed |
20th century
|
| gptkbp:notTreatedWith |
antipsychotics
beta blockers alone |
| gptkbp:riskFactor |
recreational drug use
polypharmacy pediatric exposure therapeutic overdose |
| gptkbp:treatment |
gptkb:benzodiazepines
supportive care antihypertensives cooling measures |
| gptkbp:bfsParent |
gptkb:anticholinergic_toxicity
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
sympathomimetic toxicity
|